Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

Tumor angiogenesis: therapeutic implications

Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · see citing works

The biology of VEGF and its receptors

Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · see citing works

Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O ₂ -Regulated Prolyl Hydroxylation

Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535 · see citing works

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · see citing works

Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen

Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,988 · see citing works

HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O ₂ Sensing

Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · see citing works

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617 · see citing works

The Biology of Vascular Endothelial Growth Factor

Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,540 · see citing works

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,114 · see citing works

Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid

Senger, D. R., Galli, S. J., Dvořàk, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,969 · see citing works

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931 · see citing works

Angiogenic Factors

Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,783 · see citing works

Vascular Endothelial Growth Factor: Basic Science and Clinical Progress

Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,707 · see citing works

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O’Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,624 · see citing works

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · see citing works

Tumorigenesis and the angiogenic switch

Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559 · see citing works

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797 · see citing works

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

Yang, J. C., Haworth, L. R., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,681 · see citing works

Transplacental Carcinogenesis by Stilbestrol

Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640 · see citing works

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.

Soker, S., Takashima, S., Miao, H., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,634 · see citing works

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

Fong, G.-H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995) · Nature · doi:10.1038/376066a0 · Cited by 2,606 · see citing works

Regulation of angiogenesis by hypoxia: role of the HIF system

Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520 · see citing works

Molecular regulation of vessel maturation

Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,515 · see citing works

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

Ferrara, N., & Henzel, W. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92678-8 · Cited by 2,269 · see citing works

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo

Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,262 · see citing works

A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer

Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B., Pitot, H. C., & Alberts, S. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,251 · see citing works

Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · see citing works

VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation

Gerber, H. P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, Z., & Ferrara, N. (1999) · Nature Medicine · doi:10.1038/9467 · Cited by 2,089 · see citing works

Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF

Keck, P. J., Hauser, S. D., Krivi, G. G., Sanzo, K., Warren, T. G., Feder, J., & Connolly, D. T. (1989) · Science · doi:10.1126/science.2479987 · Cited by 2,058 · see citing works

The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor

de Vries, C. J. M., Escobedo, J. A., Ueno, H., Houck, K. A., Ferrara, N., & Williams, L. T. (1992) · Science · doi:10.1126/science.1312256 · Cited by 2,019 · see citing works

Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway

Gerber, H. P., McMurtrey, A. E., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V. M., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,976 · see citing works

The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing

Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., & Abraham, J. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99049-6 · Cited by 1,972 · see citing works

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966 · see citing works

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

Millauer, B., Wizigmann-Voos, S., Schnürch, H., Martínez, R., Møller, N. P. H., Risau, W., & Ullrich, A. (1993) · Cell · doi:10.1016/0092-8674(93)90573-9 · Cited by 1,925 · see citing works

Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

Kabbinavar, F. F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Liebérman, G., Griffing, S., & Bergsland, E. K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,711 · see citing works

VEGF-Trap: A VEGF blocker with potent antitumor effects

Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · see citing works

A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases.

Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N., & Alitalo, K. K. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00359.x · Cited by 1,668 · see citing works

Isolation of a tumor factor responsible for angiogenesis

Folkman, J., Merler, E., Abernathy, C., & Williams, G. (1971) · The Journal of Experimental Medicine · doi:10.1084/jem.133.2.275 · Cited by 1,663 · see citing works

von Hippel-Lindau disease

Lonser, R. R., Glenn, G. M., Walther, M. M., Chew, E. Y., Libutti, S. K., Linehan, W. M., & Oldfield, E. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13643-4 · Cited by 1,615 · see citing works

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,602 · see citing works

Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy

Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,574 · see citing works

VEGF and the quest for tumour angiogenesis factors

Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536 · see citing works

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D. S., Armellino, D. C., Gospodarowicz, D., & Böhlen, P. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)90483-2 · Cited by 1,519 · see citing works

Clinical translation of angiogenesis inhibitors

Kerbel, R. S., & Folkman, J. (2002) · Nature reviews. Cancer · doi:10.1038/nrc905 · Cited by 1,513 · see citing works

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,391 · see citing works

The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA

Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B., & Leung, D. W. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-12-1806 · Cited by 1,364 · see citing works

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. K., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,361 · see citing works

Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1

Barleon, B., Sozzani, S., Zhou, D., Weich, H., Mantovani, A., & Marmé, D. (1996) · Blood · doi:10.1182/blood.v87.8.3336.bloodjournal8783336 · Cited by 1,350 · see citing works

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

Eremina, V., Sood, M. M., Haigh, J. J., Nagy, A., Lajoie, G., Ferrara, N., Gerber, H. P., Kikkawa, Y., Miner, J. H., & Quaggin, S. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17423 · Cited by 1,308 · see citing works

Structural Characterization and Biological Functions of Fibroblast Growth Factor

Gospodarowicz, D., Ferrara, N., Schweigerer, L., & Neufeld, G. (1987) · Endocrine Reviews · doi:10.1210/edrv-8-2-95 · Cited by 1,273 · see citing works

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,234 · see citing works

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

Millauer, B., Shawver, L. K., Plate, K. H., Risaui, W., & Ullrich, A. (1994) · Nature · doi:10.1038/367576a0 · Cited by 1,219 · see citing works

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Bergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192 · see citing works

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Klement, G. L., Baruchel, S., Rak, J. W., Man, S., Clark, K., Hicklin, D. J., Böhlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,166 · see citing works

Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms.

Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J., & Ferrara, N. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35712-0 · Cited by 1,127 · see citing works

The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

Park, J. E., Keller, G. A., & Ferrara, N. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.12.1317 · Cited by 1,123 · see citing works

Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.

Park, J. E., Chen, H. H., Winer, J., Houck, K. A., & Ferrara, N. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47298-5 · Cited by 1,112 · see citing works

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1

Luttun, A., Tjwa, M., Moons, L., Wu, Y. L., Angelillo‐Scherrer, A., Liao, F., Nagy, J. A., Hooper, A. T., Priller, J., Klerck, B. D., et al. (2002) · Nature Medicine · doi:10.1038/nm731 · Cited by 1,067 · see citing works

Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.

Maglione, D., Guerriero, V., Viglietto, G., Bovi, P. D., & Persico, M. G. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.9267 · Cited by 998 · see citing works

Tumor Induction of VEGF Promoter Activity in Stromal Cells

Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996 · see citing works

Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells

Gerber, H., Dixit, V. M., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.13313 · Cited by 990 · see citing works

Regulators of Angiogenesis

Klagsbrun, M., & D'Amore, P. A. (1991) · Annual Review of Physiology · doi:10.1146/annurev.ph.53.030191.001245 · Cited by 961 · see citing works

Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family.

Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., & Sato, M. (1990) · PubMed · Cited by 960 · see citing works

Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesisPreprint

Ruhrberg, C., Gerhardt, H., Golding, M., Watson, R., Ioannidou, S., Fujisawa, H., Betsholtz, C., & Shima, D. T. (2002) · Genes & Development · doi:10.1101/gad.242002 · Cited by 918 · see citing works

VEGF is required for growth and survival in neonatal mice

Gerber, H., Hillan, K. J., Ryan, A. M., Kowalski, J., Keller, G.-A., Rangell, L. K., Wright, B. D., Radtke, F., Aguet, M., & Ferrara, N. (1999) · Development · doi:10.1242/dev.126.6.1149 · Cited by 913 · see citing works

Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

Gordon, M. S., Margolin, K. A., Talpaz, M., Sledge, G. W., Holmgren, E. B., Benjamin, R. S., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913 · see citing works

MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis

Hiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., Shipley, J. M., Senior, R. M., & Shibuya, M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00153-8 · Cited by 910 · see citing works

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., & Goldberg, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10595 · Cited by 882 · see citing works

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 844 · see citing works

Lymphangiogenesis and cancer metastasis

Stacker, S. A., Achen, M. G., Jussila, L., Baldwin, M. E., & Alitalo, K. K. (2002) · Nature reviews. Cancer · doi:10.1038/nrc863 · Cited by 798 · see citing works

Vascular endothelial growth factor B, a novel growth factor for endothelial cells.

Olofsson, B., Pajusola, K., Kaipainen, A., von Euler, G., Joukov, V., Saksela, O., Orpana, A., Pettersson, R. F., Alitalo, K. K., & Eriksson, U. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2576 · Cited by 796 · see citing works

Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium.

Quinn, T. P., Peters, K. G., de Vries, C. J. M., Ferrara, N., & Williams, L. T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7533 · Cited by 754 · see citing works

2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165)

Ruckman, J., Green, L. S., Beeson, J., Waugh, S. M., Gillette, W. L., Henninger, D. D., Claesson, L., & Janjić, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744 · see citing works

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody

Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719 · see citing works

VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism

Gerber, H., Malik, A. K., Solar, G. P., Sherman, D. A., Liang, X. H., Meng, G., Hong, K., Marsters, J. C., & Ferrara, N. (2002) · Nature · doi:10.1038/nature00821 · Cited by 706 · see citing works

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.

Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A., & Ferrara, N. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117857 · Cited by 694 · see citing works

Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1

LeCouter, J. E., Moritz, D. R., Li, B., Phillips, G. D. L., Liang, X. H., Gerber, H., Hillan, K. J., & Ferrara, N. (2003) · Science · doi:10.1126/science.1079562 · Cited by 677 · see citing works

Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.

Lee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 674 · see citing works

Host cyclooxygenase-2 modulates carcinoma growth

Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., & DuBois, R. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9621 · Cited by 672 · see citing works

Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

Prewett, M. C., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K. D., Overholser, J. C., Hooper, A. T., Pytowski, B., Witte, L., et al. (1999) · PubMed · Cited by 660 · see citing works

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies

Morgan, B., Thomas, A., Drevs, J., Hennig, J., Büchert, M., Jivan, A., Horsfield, M. A., Mross, K., Ball, H. A., Lee, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.092 · Cited by 653 · see citing works

Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment

Hattori, K., Heissig, B., Wu, Y. L., Dias, S., Tejada, R., Ferris, B., Hicklin, D. J., Zhu, Z., Böhlen, P., Witte, L., et al. (2002) · Nature Medicine · doi:10.1038/nm740 · Cited by 632 · see citing works

Vascular endothelial growth factor is essential for corpus luteum angiogenesis

Ferrara, N., Chen, H., Davis-Smyth, T., Gerber, H. P., Nguyen, T.-N., Peers, D. H., Chisholm, V., Hillan, K. J., & SCHWALL, R. H. (1998) · Nature Medicine · doi:10.1038/nm0398-336 · Cited by 624 · see citing works

The Carboxyl-terminal Domain(111–165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency

Keyt, B. A., Berleau, L. T., Nguyen, H. V., Chen, H., Heinsohn, H. G., VANDLEN, R. L., & Ferrara, N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7788 · Cited by 603 · see citing works

Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice

Sonoshita, M., Takaku, K., Sasaki, N., Sugimoto, Y., Ushikubi, F., Narumiya, S., Oshima, M., & Taketo, M. M. (2001) · Nature Medicine · doi:10.1038/nm0901-1048 · Cited by 587 · see citing works

Blood vessels and nerves: common signals, pathways and diseases

Carmeliet, P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1158 · Cited by 513 · see citing works

Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT‐20 cells.

Plouët, J., Schilling, J., & Gospodarowicz, D. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08557.x · Cited by 495 · see citing works

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

Cobleigh, M. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.013 · Cited by 489 · see citing works

Vasculae Reactions of Normal and Malignant Tissues in Vivo. I. Vascular Reactions of Mice to Wounds and to Normal and Neoplastic Transplants

Algire, G. H., Chalkley, H. W., Legallais, F. Y., & Park, H. D. (1945) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/6.1.73 · Cited by 472 · see citing works

During angiogenesis, vascular endothelial growth factor regulate natural killer cell adhesion to tumor endothelium

Melder, R. J., Koenig, G. C., Witwer, B. P., Safabakhsh, N., Munn, L. L., & Jain, R. K. (1996) · Nature Medicine · doi:10.1038/nm0996-992 · Cited by 451 · see citing works

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigen 1 1Edited by I. A. Wilson

Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., de Vos, A. M., & Lowman, H. B. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3192 · Cited by 447 · see citing works

Correction to: A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases.

Joukov, V., Pajusola, K., Kaipainen, A., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00521.x · Cited by 432 · see citing works

Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia.

Zhang, X., Gaspard, J. P., & Chung, D. C. (2001) · PubMed · Cited by 425 · see citing works

Angiogenesis Ischemic and Neoplastic Disorders

Semenza, G. L. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152418 · Cited by 386 · see citing works

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis

Inoue, M., Hager, J. H., Ferrara, N., Gerber, H., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00031-4 · Cited by 380 · see citing works

Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer.

Yoshiji, H., Gomez, D. E., Shibuya, M., & Thorgeirsson, U. P. (1996) · PubMed · Cited by 369 · see citing works

HIF hydroxylation and the mammalian oxygen-sensing pathway

Safran, M., & Kaelin, W. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318181 · Cited by 365 · see citing works

HIF hydroxylation and the mammalian oxygen-sensing pathway

Safran, M., & Kaelin, W. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18181 · Cited by 363 · see citing works

Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data

Margolin, K. A., Gordon, M. S., Holmgren, E. B., Gaudreault, J., Novotny, W. F., Fyfe, G., Adelman, D. C., Stalter, S., & Breed, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.851 · Cited by 360 · see citing works

Cytokine traps: multi-component, high-affinity blockers of cytokine action

Economides, A. N., Carpenter, L. R., Rudge, J. S., Wong, V., Koehler-Stec, E. M., Hartnett, C., Pyles, E. A., Xu, X., Daly, T. J., Young, M. R., et al. (2002) · Nature Medicine · doi:10.1038/nm811 · Cited by 360 · see citing works

Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders

Autiero, M., Luttun, A., Tjwa, M., & Carmeliet, P. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00263.x · Cited by 358 · see citing works

Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.

Saleh, M., Stacker, S. A., & Wilks, A. F. (1996) · PubMed · Cited by 356 · see citing works

Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor

Maglione, D. (1991) · Medical Entomology and Zoology · Cited by 352 · see citing works

Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy.

Borgström, P., Hillan, K. J., Sriramarao, P., & Ferrara, N. (1996) · PubMed · Cited by 331 · see citing works

Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells

Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., & Marmé, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25915 · Cited by 329 · see citing works

Flk-1 as a target for tumor growth inhibition.

Strawn, L. M., McMahon, G., App, H., Schreck, R., Kuchler, W. R., Longhi, M. P., Hui, T. H., Tang, C., Levitzki, A., Gazit, A., et al. (1996) · PubMed · Cited by 317 · see citing works

Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family.

Orlandini, M., Marconcini, L., Ferruzzi, R., & Oliviero, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11675 · Cited by 313 · see citing works

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

Kim, E. S., Serur, A., Huang, J., Manley, C. A., McCrudden, K. W., Frischer, J. S., Soffer, S. Z., Ring, L. E., New, T. N., Zabski, S. M., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398399 · Cited by 312 · see citing works

Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.

Byrne, A. T., Ross, L. H., Holash, J., Nakanishi, M., Hu, L., Hofmann, J., Yancopoulos, G. D., & Jaffe, R. B. (2003) · PubMed · Cited by 310 · see citing works

Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts.

Kozin, S. V., Boucher, Y., Hicklin, D. J., Böhlen, P., Jain, R. K., & Suit, H. D. (2001) · PubMed · Cited by 293 · see citing works

Human Vascular Permeability Factor

Connolly, D. T., Olander, J. V., Heuvelman, D. M., Nelson, R. M., Monsell, R., Siegel, N. R., Haymore, B. L., Leimgruber, R. M., & Feder, J. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47212-8 · Cited by 291 · see citing works

Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.

Seno, H., Oshima, M., Ishikawa, T., Oshima, H., Takaku, K., Chiba, T., Narumiya, S., & Taketo, M. M. (2002) · PubMed · Cited by 289 · see citing works

Tumor Angiogenesis: Transfilter Diffusion Studies in the Hamster by the Transparent Chamber Technique 2

Greenblatt, M., & Shubi, P. (1968) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/41.1.111 · Cited by 283 · see citing works

Vascular endothelial grouth facter B, a novel growth facter for endothelial cells

Olffson, B. (1996) · Medical Entomology and Zoology · Cited by 279 · see citing works

Vascular Endothelial Growth Factor is Expressed in Rat Corpus Luteum

PHILLIPS, H. S., Hains, J. M., LEUNG, D. W., & Ferrara, N. (1990) · Endocrinology · doi:10.1210/endo-127-2-965 · Cited by 277 · see citing works

Impact of oncogenes in tumor angiogenesis: Mutant K- ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells

Okada, F., Rak, J. W., Croix, B. S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3609 · Cited by 269 · see citing works

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer

Kuo, C. J., Farnebo, F. A., Yu, E. Y., Christofferson, R. H. B., Swearingen, R. A., Carter, R., von Recum, H. A., Yuan, J., Kamihara, J., Flynn, E. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081615298 · Cited by 268 · see citing works

Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary

Ravindranath, N., LITTLE-IHRIG, L. L., PHILLIPS, H. S., Ferrara, N., & Zeleznik, A. J. (1992) · Endocrinology · doi:10.1210/endo.131.1.1612003 · Cited by 265 · see citing works

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 å resolution and mutational analysis of the interface

Muller, Y. A., Chen, Y., Christinger, H. W., Li, B., Cunningham, B. C., Lowman, H. B., & de Vos, A. M. (1998) · Structure · doi:10.1016/s0969-2126(98)00116-6 · Cited by 263 · see citing works

Placenta Growth Factor

Persico, M. G. (2001) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-0213-4_16 · Cited by 259 · see citing works

Requirements for Binding and Signaling of the Kinase Domain Receptor for Vascular Endothelial Growth Factor

Fuh, G., Li, B., Crowley, C. W., Cunningham, B. C., & Wells, J. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.18.11197 · Cited by 258 · see citing works

Preclinical Pharmacokinetics, Interspecies Scaling, and Tissue Distribution of a Humanized Monoclonal Antibody against Vascular Endothelial Growth Factor

Lin, Y. S., Nguyen, C. B., Mendoza, J.-L., Escandón, E., Fei, D., Meng, Y. G., & Modi, N. B. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37962-5 · Cited by 256 · see citing works

Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors.

Tsuzuki, Y., Fukumura, D., Oosthuyse, B., Koike, C., Carmeliet, P., & Jain, R. K. (2000) · PubMed · Cited by 255 · see citing works

Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.

Gerber, H., Kowalski, J., Sherman, D. A., Eberhard, D. A., & Ferrara, N. (2000) · PubMed · Cited by 249 · see citing works

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

Borgström, P., Bourdon, M. A., Hillan, K. J., Sriramarao, P., & Ferrara, N. (1998) · The Prostate · doi:10.1002/(sici)1097-0045(19980401)35:1 · Cited by 248 · see citing works

Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber

Ide, A. (1939) · American Journal of Roentgenology · Cited by 237 · see citing works

The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle

Bassett, D. L. (1943) · American Journal of Anatomy · doi:10.1002/aja.1000730206 · Cited by 211 · see citing works

Magnetic Resonance Imaging Detects Suppression of Tumor Vascular Permeability After Administration of Antibody to Vascular Endothelial Growth Factor

Pham, C. D., Roberts, T. P. L., van Bruggen, N., Melnyk, O. O., Mann, J. S., Ferrara, N., Cohen, R. L., & Brasch, R. C. (1998) · Cancer Investigation · doi:10.3109/07357909809039771 · Cited by 208 · see citing works

Suppression of Luteal Angiogenesis in the Primate after Neutralization of Vascular Endothelial Growth Factor1

Fraser, H. M., Dickson, S. E., Lunn, S. F., Wulff, C., Morris, K. D., Carroll, V. A., & Bicknell, R. (2000) · Endocrinology · doi:10.1210/endo.141.3.7369 · Cited by 205 · see citing works

Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal Antibody

Ryan, A. M., Eppler, D. B., Hagler, K. E., Bruner, R. H., Thomford, P. J., Hall, R. L., Shopp, G. M., & O’neill, C. A. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700115 · Cited by 202 · see citing works

The role of VEGF in normal and neoplastic hematopoiesis

Gerber, H., & Ferrara, N. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0397-4 · Cited by 201 · see citing works

Molecular cloning, sequencing and expression of the mRNA encoding human Cdx1 and Cdx2 homeobox. Down-regulation of Cdx1 and Cdx2 mRNA expression during colorectal carcinogenesis

Mallo, G. V., Rechreche, H., Frigerio, J.-M., Rocha, D., Zweibaum, A., Lacasa, M., Jordan, B., Dusetti, N., Dagorn, J., & Iovanna, J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970220)74:1 · Cited by 200 · see citing works

The second immunoglobulin‐like domain of the VEGF tyrosine kinase receptor Flt‐1 determines ligand binding and may initiate a signal transduction cascade.

Davis-Smyth, T., Chen, H., Park, J., Presta, L. G., & Ferrara, N. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00872.x · Cited by 199 · see citing works

Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.

Borgström, P., Gold, D. P., Hillan, K. J., & Ferrara, N. (1999) · PubMed · Cited by 196 · see citing works

ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.

Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Curwen, J., Hennequin, L. F., Thomas, A., Stokes, E. S. E., Curry, B. J., Richmond, G., et al. (2000) · PubMed · Cited by 193 · see citing works

Extracellular Proteolysis and Angiogenesis

Pepper, M. S. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616232 · Cited by 190 · see citing works

Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis.

Matsuzaki, K., Yoshitake, Y., Matuo, Y., et al. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.9911 · Cited by 165 · see citing works

Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma

Ellis, L. M., Takahashi, Y., Fenoglio, C. J., et al. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10068-5 · Cited by 160 · see citing works

Irinotecan Plus Fluorouracil/Leucovorin for Metastatic Colorectal Cancer: A New Survival Standard

Saltz, L. B., Douillard, J., Pirotta, N., Alakl, M. K., Gruia, G., Awad, L., Elfring, G. L., Locker, P. K., & Miller, L. L. (2001) · The Oncologist · doi:10.1634/theoncologist.6-1-81 · Cited by 147 · see citing works

Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma

Tomisawa, M., Tokunaga, T., Oshika, Y., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00278-0 · Cited by 143 · see citing works

血小板由来増殖因子/血管内皮増殖因子ファミリーと相関するc‐fos誘導性遺伝子の同定

Orlandini, M., Marconcini, L., Ferruzzi, R., & Oliviero, S. (1996) · Cited by 138 · see citing works

Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts.

Oku, T., Tjuvajev, J. G., Miyagawa, T., et al. (1998) · PubMed · Cited by 136 · see citing works

Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth.

Melnyk, O. O., Shuman, M. A., & Kim, K. J. (1996) · PubMed · Cited by 133 · see citing works

Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis.

Shima, D. T., Gougos, A., Miller, J. W., Tolentino, M. J., ROBINSON, G. C., Adamis, A. P., & D'Amore, P. A. (1996) · PubMed · Cited by 126 · see citing works

Choriocarcinoma: Transfilter Stimulation of Vasoproliferation in the Hamster Cheek Pouch—Studied by Light and Electron Microscopy 2

Ehrmann, R. L., & Knoth, M. (1968) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/41.6.1329 · Cited by 119 · see citing works

Regulation of HIF by the von Hippel‐Lindau Tumour Suppressor: Implications for Cellular Oxygen Sensing

Mole, D. R., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. (2001) · IUBMB Life · doi:10.1080/15216540252774757 · Cited by 117 · see citing works

Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors.

Sowter, H., Corps, A. N., Evans, A. L., et al. (1997) · PubMed · Cited by 114 · see citing works

Thyroid Hormone Negatively Regulates the Transcriptional Activity of the β-Amyloid Precursor Protein Gene

Belandia, B., Latasa, M. J., Villa, A., & Pascual, A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30366 · Cited by 112 · see citing works

Angiogenesis and Oncogenesis

Gullino, P. M. (1978) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/61.3.639 · Cited by 110 · see citing works

Injection of Soluble Vascular Endothelial Growth Factor Receptor 1 into the Preovulatory Follicle Disrupts Ovulation and Subsequent Luteal Function in Rhesus Monkeys1

Hazzard, T. M., Xu, F., & Stouffer, R. L. (2002) · Biology of Reproduction · doi:10.1095/biolreprod67.4.1305 · Cited by 107 · see citing works

Short-Term Administration of Antivascular Endothelial Growth Factor Antibody in the Late Follicular Phase Delays Follicular Development in the Rhesus Monkey1

Zimmermann, R. C., Xiao, E., Husami, N., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7181 · Cited by 96 · see citing works

Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy

Smith, J. K., Mamoon, N. M., & Duhé, R. J. (2003) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/000000003772462298 · Cited by 94 · see citing works

Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy

Curé, H., Amat, S., Penault-Llorca, F. M., et al. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1020274709327 · Cited by 74 · see citing works

Short-Term Administration of Antivascular Endothelial Growth Factor Antibody in the Late Follicular Phase Delays Follicular Development in the Rhesus Monkey

Zimmermann, R. C. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.768 · Cited by 71 · see citing works

A Phase II Trial of Humanized Anti‐Vascular Endothelial Growth Factor Antibody for the Treatment of Androgen‐Independent Prostate Cancer

Reese, D., Fratesi, P., Corry, M., et al. (2001) · The Prostate Journal · doi:10.1046/j.1525-1411.2001.32007.x · Cited by 68 · see citing works

Angiogenesis inhibitors suffer new setback

Garber, K. (2002) · Nature Biotechnology · doi:10.1038/nbt1102-1067 · Cited by 56 · see citing works

Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial

Kindler, H. L., Friberg, G. R., Stadler, W. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.4009 · Cited by 45 · see citing works

Studies on the role of basic fibroblast growth factor in vivo: Inability of neutralizing antibodies to block tumor growth

Dennis, P. A., & Rifkin, D. B. (1990) · Journal of Cellular Physiology · doi:10.1002/jcp.1041440112 · Cited by 40 · see citing works

OncogenicrasFails to Restore anin VivoTumorigenic Phenotype in Embryonic Stem Cells Lacking Vascular Endothelial Growth Factor (VEGF)

Shi, Y., & Ferrara, N. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9966 · Cited by 39 · see citing works

A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors

Richly, H., Kupsch, P., Passage, K. J., et al. (2003) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp41620 · Cited by 29 · see citing works

977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer

Herbst, R. S., Mininberg, E. D., Henderson, T., et al. (2003) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(03)91004-4 · Cited by 17 · see citing works

Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · see citing works

VEGF in signaling and disease: beyond discovery and development

Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721 · see citing works

Influence of tumour micro-environment heterogeneity on therapeutic response

Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694 · see citing works

Angiogenesis as a therapeutic target

Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · see citing works

Engineered Nanoparticles for Drug Delivery in Cancer Therapy

Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164 · see citing works

How were new medicines discovered?

Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812 · see citing works

Principles of cancer therapy: oncogene and non-oncogene addiction

Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765 · see citing works

Targeting metastasis

Steeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363 · see citing works

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation

Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170 · see citing works

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association

Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153 · see citing works

Pancreatic cancer stroma: an update on therapeutic targeting strategies

Hosein, A. N., Brekken, R. A., & Maitra, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0300-1 · Cited by 950 · see citing works

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells

Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · see citing works

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849 · see citing works

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq020 · Cited by 638 · see citing works

Bevacizumab plus ipilimumab in patients with metastatic melanoma

Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593 · see citing works

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604 · see citing works

Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors

Butler, J. M., Kobayashi, H., & Rafii, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2791 · Cited by 578 · see citing works

Biomarkers of response and resistance to antiangiogenic therapy

Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572 · see citing works

Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy

Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546 · see citing works

Regulation of cancer cell metabolism by hypoxia-inducible factor 1

Semenza, G. L. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.009 · Cited by 469 · see citing works

Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?

Stefani, C., Miricescu, D., Stanescu-Spinu, I.-I., Nica, R. I., Greabu, M., Totan, A. R., & Jinga, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910260 · Cited by 402 · see citing works

Translating p53 into the clinic

Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · see citing works

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-angiogenic drugs

Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337 · see citing works

Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain

Andres, R. H., Horie, N., Slikker, W., Keren-Gill, H., Zhan, K., Sun, G., Manley, N. C., Pereira, M. P., Sheikh, L. A., McMillan, E. L., et al. (2011) · Brain · doi:10.1093/brain/awr094 · Cited by 329 · see citing works

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

Soria, J.-C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., Burcoveanu, D., Fukuoka, M., Besse, B., & Pignon, J.-P. (2013) · Annals of Oncology · doi:10.1093/annonc/mds590 · Cited by 314 · see citing works

Common Musculoskeletal Tumors of Childhood and Adolescence

Arndt, C. A. S., Rose, P. S., Folpe, A. L., & Laack, N. N. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.01.015 · Cited by 298 · see citing works

Molecular imaging of the tumor microenvironment

Zhou, Z., & Lu, Z.-R. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.07.012 · Cited by 253 · see citing works

INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS

PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255 · see citing works

Transplanted Stem Cell-Secreted Vascular Endothelial Growth Factor Effects Poststroke Recovery, Inflammation, and Vascular Repair

Horie, N., Pereira, M. P., Niizuma, K., Sun, G., Keren-Gill, H., Encarnacion, A., Shamloo, M., Hamilton, S. A., Jiang, K., Huhn, S., et al. (2011) · Stem Cells · doi:10.1002/stem.584 · Cited by 240 · see citing works

HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma

Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1459 · Cited by 188 · see citing works

Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma

Lu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179 · see citing works

Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect

Huang, D., Sun, L., Huang, L., & Chen, Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020124 · Cited by 176 · see citing works

A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy

Kong, D.-H., Kim, M., Jang, J., Na, H.-J., & Lee, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081786 · Cited by 161 · see citing works

Notch signaling in developmental and tumor angiogenesis

Kofler, N. M., Shawber, C. J., Kangsamaksin, T., Reed, H. O., Galatioto, J., & Kitajewski, J. (2011) · Genes & Cancer · doi:10.1177/1947601911423030 · Cited by 142 · see citing works

Time Trends in the Incidence and Causes of Blindness in Israel

Skaat, A., Chetrit, A., Belkin, M., Kinori, M., & Kalter-Leibovici, O. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.08.035 · Cited by 115 · see citing works

Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs

Hongu, T., Pein, M., Insua-Rodríguez, J., Gutjahr, E., Mattavelli, G., Meier, J., Decker, K., Descot, A., Bozza, M., Harbottle, R., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00353-6 · Cited by 118 · see citing works

Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis

Lima, A. B. C., Macedo, L. T., & Sasse, A. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022681 · Cited by 92 · see citing works

Current targeted therapies in the treatment of advanced colorectal cancer: a review

Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87 · see citing works

Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro

O'Neill, E. C., Qin, Q., Van Bergen, N. J., Connell, P. P., Vasudevan, S., Coote, M. A., Trounce, I. A., Wong, T. T. L., & Crowston, J. G. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5669 · Cited by 73 · see citing works

Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells

Naik, E., O'Reilly, L. A., Asselin-Labat, M.-L., Merino, D., Lin, A., Cook, M., Coultas, L., Bouillet, P., Adams, J. M., & Strasser, A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100951 · Cited by 31 · see citing works

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

Brugarolas, J., Obara, G., Beckermann, K. E., Rini, B., Lam, E. T., Hamilton, J., Schluep, T., Yi, M., Wong, S., Mao, Z. L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3029 · Cited by 25 · see citing works

Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration

Khanani, A. (2015) · Clinical Ophthalmology · doi:10.2147/opth.s88624 · Cited by 10 · see citing works

Development of Dendritic Cell-Based Immunotherapy Targeting Tumor Blood Vessels in a Mouse Model of Lung Metastasis

Nomura, T., Yamakawa, M., Shimaoka, T., Hirai, T., Koizumi, N., Maruyama, K., & Utoguchi, N. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00737 · Cited by 6 · see citing works

Comparison of Serum Concentrations of Bevacizumab and Vascular Endothelial Growth Factor (VEGF) Levels in Laser and Bevacizumab Treated ROP Patients

Kong, L., Bhatt, A. R., Demny, A. B., et al. (2014) · Investigative Ophthalmology & Visual Science

Περιεγχειρητική διακύμανση του αυξητικού παράγοντα αγγειακού ενδοθηλίου (vascular endothelial growth factor/VEGF) σε ασθενείς με καρκίνο παχέος εντέρου και ασθενείς με καρκίνο μαστού

Μπιτσάκου, Γ. (2013) · doi:10.12681/eadd/41000

Expression of total vascular endothelial growth factor (VEGF) and inhibitory isoforms of VEGF in head and neck squamous cell carcinoma

Wilkie, M. D., Santosh, S., Emmett, M. S., et al. (2012) · International Journal of Surgery · doi:10.1016/j.ijsu.2012.06.015

Serum vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1) and sVEGFR-2 in systemic sclerosis patients: Relation to clinical manifestations and capillaroscopy findings

Shenavandeh, S., Tarakemeh, T., Sarvestani, E. K., & Nazarinia, M. A. (2016) · The Egyptian Rheumatologist · doi:10.1016/j.ejr.2016.03.004 · Cited by 19 · see citing works

The Effect of VEGF (Vascular endothelial growth factor) on Endothelial Cells in Pathogenesis of Preeclampsia

Cho, Y.-K., & 이홍균 (2002) · Obstetrics & Gynecology Science